ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

Phase 3RinzimetostatNUBEQAPositive

AI Analysis

Summary

ORIC Pharmaceuticals has initiated the Himalayas-1 Phase 3 trial evaluating Rinzimetostat in combination with Bayer's NUBEQA (Darolutamide) in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone.

Clinical Trial Data

Phase

Phase 3

Importance:6/10

Sentiment:

0.30

Phase 3 TrialmCRPCCombination TherapyClinical CollaborationTrial Initiation

Related Companies

$ORIC $BAYRY

Read the original article

Published by GlobeNewswire Clinical Studies on July 14, 2026 8:05 PM

Read Original